Selected Drugs Clear All
MultiCheck Results
- 0
Interaction
Additional Considerations |
||
|
tarlatamab
in Imdelltra (tarlatamab-dlle)
|
||
|
caution advised with narrow therapeutic index drugs, especially during and up to 14 days after CRS; tarlatamab may incr. cytokine release leading to suppression of metabolic enzymes, may cause incr. levels of CYP450 substrates, risk of adverse effects |
||